PT  - JOURNAL ARTICLE
AU  - Cynthia L. Gentry
AU  - Lincoln H. Wilkins, Jr.
AU  - Ronald J. Lukas
TI  - Effects of Prolonged Nicotinic Ligand Exposure on Function of Heterologously Expressed, Human α4β2- and α4β4-Nicotinic Acetylcholine Receptors
AID  - 10.1124/jpet.102.041756
DP  - 2003 Jan 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 206--216
VI  - 304
IP  - 1
4099  - http://jpet.aspetjournals.org/content/304/1/206.short
4100  - http://jpet.aspetjournals.org/content/304/1/206.full
SO  - J Pharmacol Exp Ther2003 Jan 01; 304
AB  - Effects of prolonged nicotinic ligand exposure on the function of human α4β2- and α4β4-nicotinic acetylcholine receptor (nAChR) subtypes were studied using receptors heterologously expressed in SH-EP1 human epithelial cells. Magnitudes of acute, nAChR-mediated, specific 86Rb+ efflux responses to 1 mM carbamylcholine were reduced after pretreatment with specific nAChR ligands in effects that depended on pretreatment drug dose, duration of drug pretreatment, and duration of drug-free recovery. Fifty percent inhibition of α4β2-nAChR function following 5 min of recovery occurred after 1 min of pretreatment with 1 mM nicotine but also after 1-h pretreatment at 10 nM nicotine. Seventy-five percent loss in function persisted 1 h after drug removal following 15 min or more of exposure to 1 mM nicotine. However, functional recovery was nearly complete after 1 h in drug-free medium following 1 min to 24 h pretreatment with 0.1 to 1 μM nicotine, i.e., in the range of smoker plasma nicotine levels. α4β4-nAChR was similarly sensitive to persistent inactivation by prolonged nicotine exposure. Carbamylcholine exhibited slightly lower persistent inactivation potency than nicotine at both α4β2- and α4β4-nAChR. The nAChR antagonist, mecamylamine, exhibited persistent inactivation potency and efficacy similar to nicotine at α4β2-nAChR but had a reduced effect on α4β4-nAChR. These studies illustrate persistent inactivation of human α4β2- or α4β4-nAChR induced by prolonged exposure to nicotine and show that other ligands induce nAChR persistent inactivation in a subtype-specific manner. The American Society for Pharmacology and Experimental Therapeutics